TF and B-cell chronic lymphocytic leukemia: The TF signature associated with trisomy 12 can be reversed by bromodomain inhibition and trisomy 12 samples exhibit increased sensitivity to bromodomain inhibition, indicating this as potential therapeutic strategy in trisomy 12 CLL.